JP2004529642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529642A5 JP2004529642A5 JP2002580865A JP2002580865A JP2004529642A5 JP 2004529642 A5 JP2004529642 A5 JP 2004529642A5 JP 2002580865 A JP2002580865 A JP 2002580865A JP 2002580865 A JP2002580865 A JP 2002580865A JP 2004529642 A5 JP2004529642 A5 JP 2004529642A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- phenylglycine
- atb
- derivative
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 238000000034 method Methods 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 16
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- JYGMAKXCDIVGDW-ZETCQYMHSA-N (2s)-2-amino-2-[3-[[amino(nitramido)methylidene]amino]phenyl]acetic acid Chemical group OC(=O)[C@@H](N)C1=CC=CC(NC(N)=N[N+]([O-])=O)=C1 JYGMAKXCDIVGDW-ZETCQYMHSA-N 0.000 claims 10
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 9
- 150000008574 D-amino acids Chemical class 0.000 claims 9
- 229960004203 carnitine Drugs 0.000 claims 9
- 150000005331 phenylglycines Chemical class 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 7
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 7
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 7
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 7
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 7
- 150000001412 amines Chemical class 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 150000001483 arginine derivatives Chemical group 0.000 claims 7
- 229960002173 citrulline Drugs 0.000 claims 7
- 235000013477 citrulline Nutrition 0.000 claims 7
- 229960003646 lysine Drugs 0.000 claims 7
- 229960003104 ornithine Drugs 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 230000002194 synthesizing effect Effects 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940093740 amino acid and derivative Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000000941 radioactive substance Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- KNSXYOKTTAUWDZ-ZDUSSCGKSA-N tert-butyl (2s)-2-[3-[[amino(nitramido)methylidene]amino]phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC(C)(C)C)C1=CC=CC(NC(N)=N[N+]([O-])=O)=C1 KNSXYOKTTAUWDZ-ZDUSSCGKSA-N 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28332601P | 2001-04-13 | 2001-04-13 | |
| US30616801P | 2001-07-19 | 2001-07-19 | |
| PCT/JP2002/003678 WO2002083060A2 (en) | 2001-04-13 | 2002-04-12 | Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529642A JP2004529642A (ja) | 2004-09-30 |
| JP2004529642A5 true JP2004529642A5 (https=) | 2005-12-22 |
Family
ID=26961983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002580865A Withdrawn JP2004529642A (ja) | 2001-04-13 | 2002-04-12 | 薬物およびプロドラッグの送達系としてのアミノ酸輸送体ａｔｂ０，＋の利用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040142317A1 (https=) |
| EP (1) | EP1384081A2 (https=) |
| JP (1) | JP2004529642A (https=) |
| CA (1) | CA2443732A1 (https=) |
| WO (1) | WO2002083060A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003271173A1 (en) * | 2002-10-11 | 2004-05-04 | Chugai Seiyaku Kabushiki Kaisha | Cell growth regulator |
| US20090123388A1 (en) | 2005-01-14 | 2009-05-14 | Medical College Of Georgia Research Institute | Prodrugs of Short-Chain Fatty Acids and Treatment Methods |
| WO2010042685A2 (en) * | 2008-10-08 | 2010-04-15 | Medical College Of Georgia Research Institute, Inc. | Inhibitors of the atb(0,+) transporter and uses thereof |
| US20230220387A1 (en) * | 2019-12-27 | 2023-07-13 | Kagami Inc. | D-serine transport modifier and screening method thereof, and screening method of d-serine transporter protein |
-
2002
- 2002-04-12 WO PCT/JP2002/003678 patent/WO2002083060A2/en not_active Ceased
- 2002-04-12 CA CA002443732A patent/CA2443732A1/en not_active Abandoned
- 2002-04-12 JP JP2002580865A patent/JP2004529642A/ja not_active Withdrawn
- 2002-04-12 EP EP02722695A patent/EP1384081A2/en not_active Withdrawn
- 2002-04-12 US US10/467,893 patent/US20040142317A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190060473A1 (en) | Hsp90 inhibitor drug conjugates | |
| JP2007536311A5 (https=) | ||
| JP2008543854A5 (https=) | ||
| JP2010106043A (ja) | テトラサイクリンの経口バイオアベイラビリティーを増加する方法 | |
| JP2003508484A5 (https=) | ||
| JP2007508396A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| CA2611114A1 (en) | An entacapone-containing oral dosage form | |
| UY29759A1 (es) | Formulaciones de ibandronato mejoradas | |
| JP2004534025A5 (https=) | ||
| CA2384502A1 (en) | Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer | |
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| JP2021522247A (ja) | 肝疾患における好中球エラスターゼ阻害薬の使用 | |
| JP2013509411A5 (https=) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
| US20230321022A1 (en) | Reversibly protected thiolated electrophilic fatty acids as prodrugs | |
| RU2007140243A (ru) | Способ лечения заболеваний предстательной железы, основанный на местной доставке активных веществ | |
| JP2006524252A5 (https=) | ||
| Kandula et al. | Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases | |
| JP2014530842A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| JP2004532828A5 (https=) | ||
| JP2004529642A5 (https=) | ||
| JP2004529207A5 (https=) |